Low Nitrogen Diet and Controlled Release Vitamins for CKD
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current kidney disease diets fail to effectively slow kidney disease progression in patients not on dialysis due to lack of standardized nutrition approaches, leading to malnutrition and increased risk of mortality, as they often result in protein and vitamin imbalances that exacerbate the condition.
Innovation Solution
A comprehensive treatment plan comprising a low nitrogen diet, low nitrogen protein food (Albutrix™), and a low-dose controlled release multivitamin with direct antioxidant supplementation to ensure safe and measurable reduction in kidney workload, addressing nutritional deficiencies and oxidative stress.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If low protein and very low protein diets are used to reduce kidney workload, then kidney workload is reduced, but malnutrition occurs which speeds kidney disease progression
Solution Approach 1:
The treatment program segments nutrition into distinct components: a low nitrogen diet framework, specific low nitrogen protein food supplements (Albutrix), and targeted vitamin/mineral supplementation. This segmentation allows precise control of nitrogen intake while ensuring complete nutrition, resolving the contradiction between reducing kidney workload and preventing malnutrition.
Solution Approach 2:
The invention changes the parameter of protein intake from conventional recommendations to a precisely controlled low nitrogen approach (specific gram per kilogram body weight ranges). It also introduces controlled release vitamin formulations with specific dosing parameters that differ from standard vitamins, optimizing nitrogen reduction while maintaining nutritional adequacy.
2Reliability
If standardized nutrition approaches are implemented, then treatment effectiveness improves, but complexity of treatment program increases
Solution Approach 1:
The treatment program serves multiple functions simultaneously: it reduces nitrogen workload on kidneys, prevents malnutrition through comprehensive vitamin/mineral supplementation, and provides standardized dosing guidelines. The low nitrogen protein food and controlled release vitamins are designed to work together as an integrated system that addresses multiple nutritional needs in one coordinated approach.
Solution Approach 2:
The invention provides preliminary standardized guidelines for diet composition, supplementation amounts, and monitoring parameters before treatment begins. This pre-established framework reduces complexity during implementation by eliminating the need for individualized calculations, while still maintaining scientific rigor and effectiveness.
3Quantity of substance
If conventional vitamins are used, then vitamin supplementation is provided, but nitrogen workload on kidneys increases
Solution Approach 1:
The controlled release vitamin formulation extracts and isolates specific vitamins and minerals from conventional multi-vitamin formulations, providing only those necessary for low nitrogen diet patients. This selective extraction eliminates unnecessary nitrogen-containing compounds while maintaining essential vitamin supplementation, directly resolving the contradiction between vitamin intake and nitrogen workload reduction.
Data Source
AI summary
A vitamin for use by kidney patients in Stages 3, 4, 4a, 4b, and 5, who are not on dialysis, comprising administering daily a: low nitrogen diet; low nitrogen protein food comprising magnesium and/or calcium salts of alpha keto acids; and time released vitamin. The vitamin comprises the active ingredients of: Zinc; Selenium; Vitamins B1, B2, B6, B12, B5, E, and K2; Niacin; superoxide dismutase; catalase; glutathione and Folate; and excludes calcium, magnesium, phosphorus, sodium, manganese, fluoride, Vitamin D and K1. The low nitrogen food contains daily up to 300 mg of nitrogen; and at least five alpha keto analogues of magnesium and/or calcium salts of: leucine, isoleucine, methionine (MEMS-II), phenylalanine (PAMS-I), and valine. Methods of making and the chemical structures MEMS-II and the PAMS-I are disclosed. The treatment results in an increase of Glomerular Filtration Rate (GFR), a decrease in blood urea levels, and a decrease in creatinine levels.